← Back to Search

Thiazolidinedione

Pioglitazone 30 Mg Oral Tablet for Prostate Cancer

Phase < 1
Waitlist Available
Led By Sameer Siddiqui, MD
Research Sponsored by St. Louis University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men between the ages of 18-85 years
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial will study the mechanisms of how a hormone-blocking therapy for prostate cancer can cause insulin resistance and evaluate a treatment to decrease that insulin resistance.

Eligible Conditions
  • Prostate Cancer
  • Insulin Resistance

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Men aged 18 to 85 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Insulin Sensitivity
Secondary outcome measures
C Reactive Protein
HOMA-IR
Insulin signaling

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Pioglitazone ArmExperimental Treatment1 Intervention
Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months. For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily.
Group II: Placebo ArmPlacebo Group1 Intervention
Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.

Find a Location

Who is running the clinical trial?

St. Louis UniversityLead Sponsor
194 Previous Clinical Trials
43,405 Total Patients Enrolled
1 Trials studying Prostate Cancer
Sameer Siddiqui, MDPrincipal Investigator - St. Louis University
SSM Cardinal Glennon Children's Hospital, St. Louis University Hospital
University Of Mo (Medical School)
Mayo Grad School Med/Mayo Fndn (Residency)
Sandeep Dhindsa, MDStudy DirectorSt. Louis University
5 Previous Clinical Trials
59 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there opportunities for new participants to join the clinical trial at this time?

"According to the information maintained on clinicaltrials.gov, this medical trial is accepting applicants at present. It was first posted in December 1st 2022 and its parameters were last adjusted November 11th 2022."

Answered by AI

Am I suitable to partake in this clinical experiment?

"This trial is inviting 44 individuals with insulin resistance, ranging in age from 18 to 85 years old. Specifically, this study seeks male participants within the same age range."

Answered by AI

Has there been prior research concerning the effectiveness of Pioglitazone 30 Mg Oral Tablet?

"Currently, 31 studies are exploring the use of Pioglitazone 30 Mg Oral Tablets with 4 trials in their third phase. These research initiatives span 69 destinations across the globe, some within Lausanne, Vaud specifically."

Answered by AI

What is the total enrollment of participants in this clinical trial?

"Affirmative. The clinicaltrials.gov website indicates that this study, initially published on December 1st 2022, is currently recruiting volunteers. 44 participants are needed across one medical centre."

Answered by AI

Are elderly individuals of eighty-five years or younger eligible for this trial?

"The requirements for this research include being between 18 and 85 years old. There are 102 studies available to those below the age of consent, while 1428 studies have been conducted with people aged over 65."

Answered by AI

What medical conditions has Pioglitazone 30 Mg Oral Tablet been found to be efficacious in treating?

"Pioglitazone 30 Mg Oral Tablet is a feasible treatment option for diabetes, diabetic neuralgia, and dietary problems."

Answered by AI
~0 spots leftby Mar 2025